BMP-9 interferes with liver regeneration and promotes liver fibrosis

Katja Breitkopf-Heinlein,1 Christoph Meyer,1 Courtney König,2 Haristi Gaitantzi,1 Annalisa Addante,3 Maria Thomas,4 Eliza Wiercinska,5 Chen Cai,1 Qi Li,1,6 Fengqi Wan,1 Claus Hellerbrand,7 Nektarios A Valous,8 Maximilian J Hahnel,9 Christian Ehlting,9 Johannes G Bode,9 Stephanie Mueller-Bohl,10 Ursula Klingmüller,10 Jutta Altenöder,1 Iryna Ilkavets,1 Marie-José Goumans,1 Lukas J A C Hawinkels,11 Se-Jun Lee,12 Matthias Wieland,2 Carolin Mogler,13 Matthias P Ebert,1 Blanca Herrera,3 Hellmut G Augustin,2,14,15 Aránzazu Sánchez,3 Steven Dooley,1 Peter ten Dijke11

ABSTRACT

Objective Bone morphogenetic protein (BMP)-9, a member of the transforming growth factor-β family of cytokines, is constitutively produced in the liver. Systemic levels act on many organs and tissues including bone and endothelium, but little is known about its hepatic functions in health and disease.

Design Levels of BMP-9 and its receptors were analysed in primary liver cells. Direct effects of BMP-9 on hepatic stellate cells (HSCs) and hepatocytes were studied in vitro, and the role of BMP-9 was examined in acute and chronic liver injury models in mice.

Results Quiescent and activated HSCs were identified as major BMP-9 producing liver cell type. BMP-9 stimulation of cultured hepatocytes inhibited proliferation, epithelial to mesenchymal transition and preserved expression of important metabolic enzymes such as cytochrome P450. Acute liver injury caused by partial hepatectomy or single injections of carbon tetrachloride (CCL4) or lipopolysaccharide (LPS) into mice resulted in transient downregulation of hepatic BMP-9 mRNA expression. Correspondingly, LPS stimulation led to downregulation of BMP-9 expression in cultured HSCs. Application of BMP-9 after partial hepatectomy significantly enhanced liver damage and disturbed the proliferative response. Chronic liver damage in BMP-9-deficient mice or in mice adenoavirally overexpressing the selective BMP-9 antagonist activin receptor-like kinase 1-Fc resulted in reduced deposition of collagen and subsequent fibrosis.

Conclusions Constitutive expression of low levels of BMP-9 stabilises hepatocyte function in the healthy liver. Upon HSC activation, endogenous BMP-9 levels increase in vitro and in vivo and high levels of BMP-9 cause enhanced damage upon acute or chronic injury.

INTRODUCTION

Bone morphogenetic proteins (BMPs) belong to the transforming growth factor (TGF)-β family of cytokines.1 Currently, about 20 different BMPs have been identified and are grouped into subfamilies, according to similarities in their amino acid sequence and action. BMPs are involved in almost all aspects of developmental biology.2 They have been shown to play a significant role in tissue repair and regeneration in many organ systems.3 For example, BMP-2, BMP-4, and BMP-7 have been implicated in bone repair and tendons.4-6 BMP-2 and BMP-7 can also promote liver regeneration.7,8 Individual BMPs can have opposite effects on cell proliferation, differentiation, and apoptosis, depending on the context of their expression.9,10 BMPs may also have additional functions in health and disease.

Bone morphogenetic protein (BMP)-9 is a high-affinity ligand for the type I receptor activin receptor-like kinase 1.11 BMP-9 is a high-affinity ligand for the type I receptor activin receptor-like kinase 1.11

What is already known on this subject?

► Bone morphogenetic protein (BMP)-9 is a member of the transforming growth factor (TGF)-β family of cytokines, is produced by the liver and is constantly secreted into the blood stream.

► BMP-9 acts antiproliferative and stabilising on mature (healthy) vessels but can promote angiogenesis in different tumours.

► BMP-9 induces epithelial to mesenchymal transition of hepatocellular carcinoma cells and its protein levels correlate with aggressiveness of hepatocellular carcinoma in patient samples.

► BMP-9 is a high-affinity ligand for the type I receptor activin receptor-like kinase 1.

What are the new findings?

► Hepatic stellate cells (HSCs) are the cellular source for BMP-9, and HSCs express and secrete increasing amounts during their fibrogenic activation.

► BMP-9 acts antiproliferative and stabilising on primary (healthy) hepatocytes including maintenance of cell polarisation and expression of metabolic enzymes like cytochrome P450 oxidases.

► Low levels of BMP-9 promote hepatic wound healing and regeneration in mouse models of acute liver damage.

► Absence or inhibition of BMP-9 during chronic liver damage (repeated injections of CCL4 to mice) significantly ameliorates fibrogenesis.

How might it impact on clinical practice in the foreseeable future?

► Transient inhibition of BMP-9 by itself or in combination with existing therapy strategies could significantly improve the hepatic wound healing and regeneration capacity upon acute as well as chronic liver injury.

Significance of this study

CrossMark
BMP-9 and BMP-10 represent the most recently discovered members of the BMP family. Whereas most BMPs signal via the type I receptors activin receptor-like kinase (ALK)2, ALK-3 or ALK-6, BMP-9 and BMP-10 show highest affinity for ALK1.11 12 Yet, cells still respond to BMP-9 in the absence of ALK1 by signalling through ALK2.11 13 Bioassay experiments have revealed high affinity of BMP-9 to ALK1 and ActRIIB and lower affinity binding to ALK2 and the other type II receptors BMPRII and ActRIIA.14 15 Whereas BMP-10 seems to be primarily expressed in the developing heart,16 BMP-9 is preferentially expressed in the liver.17 18 Constitutive low-level expression results in detectable levels of circulating BMP-9 in healthy individuals.19 20 Features distinguishing BMP-9 from other BMPs are among others that it does not bind to the BMP-co-receptor hemogenulin or the soluble BMP-antagonist noggin21 22 and that BMP-9 complexed to its prodomains is bio-
llogically active.23 It seems that upon contact with its receptors BMP-9 always turns into an active conformation, even if it is still complexed to its prodomains.24 Interestingly, BMP-9 and BMP-10 can directly bind to ALK1 and ActRIIB with similar high affinity.14 ALK1-Fc, in which the extracellular domain of ALK1 is fused to the Fc part of immunoglobulin, serves as an efficient and specific BMP-9 and BMP-10 ligand trap.25 We have recently shown that BMP-9 acts protumorigenic on liver cancer cells.6 26 However, possible functions of BMP-9 on primary non-transformed hepatocytes (HGs) have not been investigated in much detail. We therefore aimed at better characterising functions of BMP-9 in healthy and diseased liver. The data demonstrate that although physiological levels of BMP-9 seem to stabilise the epithelial phenotype of the parenchyma, high levels of BMP-9 are counteracting with cellular programmes of wound healing and/or regeneration; therefore, BMP-9 levels drop transiently during acute damage. Correspondingly, we found that hepatic wound healing in vivo is more efficient when BMP-9 is inhibited (by ALK1-Fc) or absent (in BMP-9-deficient animals).

Hepatic stellate cells (HSCs) were isolated from female Balb/c mice by pronase/collagenase digestion followed by single-step density gradient centrifugation with Nycodenz (Nyegaard Co., Oslo, Norway), essentially as previously described for rats.27 Briefly, Balb/c mice (weighing ca. 20 g) were anesthetised and the abdominal cavity was opened under sterile conditions. The liver was perfused via the portal vein with Hanks buffered balanced salt solution without Ca2+ and Mg2+. After complete perfusion, the liver was transferred to a funnel and perfused with 4×107 cells/dish in medium 1 and incubated in 5% CO2 at 37°C for 4 hours. Medium 1 was replaced with medium 2 for serum starvation and cell cycle synchronisation. On the second day, medium 2 was changed to medium 3. Hepatic stellate cells (HSCs) were isolated from female Balb/c mice by pronase/collagenase digestion followed by single-step density gradient centrifugation with Nycodenz (Nyegaard Co., Oslo, Norway), essentially as previously described for rats.27 Briefly, Balb/c mice (weighing ca. 20 g) were anesthetised and the abdominal cavity was opened under sterile conditions. The liver was perfused via the portal vein with Hanks buffered balanced salt solution without Ca2+ and Mg2+. After complete perfusion, the liver was transferred to a funnel and perfused with pronase for 4 min, followed by perfusion with collagenase for 7 min. The liver was then dissociated and the cell suspension was submitted to density gradient centrifugation with Nycodenz and washed several times. Cells were resuspended with Dulbecco’s modified Eagle’s medium (DMEM) +10% FCS. The mean purity as determined by ultra violet (UV) autofluorescence was ≥95%. The cells were then cultured in DMEM, supplemented with 4 mM L-glutamine, 10% FCS and penicillin (100 IU/mL) streptomycin (100 μg/mL). The first change of medium was performed 1–2 hours after seeding to remove any non-adherent cells and debris. For stimulation experiments with HSCs, the concentration of FCS was reduced to 0.5% overnight.

Western blot: a monoclonal rabbit anti-cleaved Smad3 (phospho S423 +S425) antibody (EP823Y) (ab52903) was used to detect phospho-Smad3/1/5/8 (αSMA) was from Abcam (ab7817) and a polyclonal rabbit antibody for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and a monoclonal mouse antibody for β-actin were obtained from Santa Cruz.

Mice

All experimental animal protocols were performed in accordance with European Community policies, and approved by local committees. BMP-9-deficient mice were generated as previously described and were maintained on a C57BL/6 background.
Scratch assay (LX-2)
LX-2 cells were cultured in 12-well plates until confluency to determine their wound-closure capacity. The cells were cultured in medium without FCS overnight. Using a pipet tip, the monolayer was scratched carefully, followed by stimulation with recombinant BMP-9 (at concentrations of 5, 10 and 50 ng/mL). Images were taken immediately (t=0 hour) and after 24 hours (seven images per scratch). The remaining diameter of the untreated condition was set as 1 and treatment conditions were expressed as ‘fold of untreated’.

Simultaneous isolation of four liver cell types from mouse liver
After isolation of primary HCs and HSCs (protocols as described above) from male C57B/6 mice, the remaining cell fraction was further processed for isolation of liver sinusoidal endothelial cells (LSECs) and Kupffer cells (KCs) using magnetic microbeads from Miltenyi (CD146 microbeads for LSEC and CD11b for KC) as described earlier.29

Human primary HSC isolation and migration assay
Primary human HSCs were isolated and cultured as described.30 In vitro activation of HSCs was achieved by cell culture on uncoated tissue culture dishes.

Migratory activity of HSCs was quantified using Cultrex 96 Well Cell Migration assay ( Trevigen, Gaithersburg, USA) as described.31 Briefly, HSCs were stimulated or not with BMP-9 for 24 hours. Subsequently, cells were trypsinised and seeded in DMEM without FCS into the upper compartment of the provided 96-well micropore plate (10×10^4 cells/well). The lower compartment was filled with DMEM supplemented with 10% FCS to assess directed migration. After incubation at 37°C for 5 hours, cell migration was quantified by fluorimetry with an EMax Microplate Reader (MWG Biotech, Ebersberg, Germany).

Immunoblot analyses
Total cell protein was harvested on ice with radioimmunoprecipitation assay lysis buffer (1×Tris-buffer, 1% Nonidet P40, 0.5% sodium deoxycholate and 0.1% sodium dodecylsulfate) in the presence of freshly added protease and phosphatase inhibitors (Roche, Mannheim, Germany). Protein concentration was measured with a Bio-Rad protein assay (Biorad, München, Germany). Proteins were separated by 4%–12% sodium dodecylsulfate/polyacrylamide gel electrophoresis (NuPAGE, Invitrogen) and transferred to nitrocellulose membranes (Pierce, Rockford, Illinois, USA). Incubation with the primary antibodies occurred at 4°C overnight. Horseradish peroxidase-linked secondary antibodies (Santa Cruz, Heidelberg, Germany) were used. The membranes were developed with Supersignal Ultra (Pierce, Hamburg, Germany), and chemiluminescence was detected digitally with a Fujiﬁlm LAS 1000 image detection system.

HC proliferation measurements
Since primary HCs in monolayer culture display only very low basal proliferative activity, a more sensitive assay to detect changes in cellular DNA content was performed as described by Huard et al.32,33 Briefly, freshly isolated HCs were plated on collagen-coated 3.5 cm plates at a density of 1.25×10^5 cells/ dish as described above. On the second day, medium 2 was changed to medium 3 and the cells were stimulated with HGF (40 ng/mL), BMP-9 (5–50 ng/mL) or a combination of both for 48 hours. In each experiment, cells derived from a single animal were used, and treatments were performed in triplicates. Cells were washed twice with phosphate buffered saline (PBS) and were frozen at −20°C. To assay DNA content, plates were incubated with 2 mL/well of Sybr Green I working solution (Sybr Green I 10 000× (Invitrogen, Darmstadt, Germany), diluted 1:2500 in PBS, supplemented with 0.1% (v/v) Triton×100 for 1 hour in the dark. Fluorescence intensity was measured using an Infinite F200 Pro plate reader (Tecan, Männedorf, Switzerland) with λ_excitation=485 nm and λ_emission=535 nm. Four experiments were performed for statistical analysis, and individual datasets were scaled to the mean of the respective experiment.

HSC proliferation experiments
Human HSCs (between passage 3 and 5 isolated from four different donors) or LX-2 cells were cultured with or without BMP-9 (5 ng/mL) for 72 hours, then the cells were dislodged by trypsin and were counted.

Determination of RNA expression
Total RNA was isolated from cells or tissue and equal amounts were reverse transcribed into cDNA. High-throughput quantitative real-time PCR (RT-PCR) analysis: total RNA was isolated from the tissue using RNeasy Mini Kit including on column genomic DNA digestion with RNase-free DNase Set (Qiagen, Hilden, Germany) and from cultured cells using high pure RNA isolation kits from Roche (Mannheim, Germany). RNA was reverse transcribed to cDNA using avian myeloblastosis virus reverse transcriptase (Roche). For quantitative RT-PCR, we used either the Fluidigm’s Biomark high-throughput quantitative (q) PCR chip platform (Fluidigm, San Francisco, California, USA) with predesigned gene expression assays from Applied Biosystems according to the manufacturer’s instructions.33 34 or regular Sybr Green-based RT-PCR was performed (40 PCR cycles on an ABI Prism 7900HT System). Primers used for RT-PCR are given in tables 1 and 2. mRNA expression levels were normalised to suitable housekeeping genes as indicated in the figure legends.

Sirius red staining and quantification
Sirius red staining was performed for 1 hour (0.1 μg Sirius red/ 100 mL picric acid; Sigma-Aldrich) as previously described.35 Samples were imaged using an Aperio slide scanner followed by whole slide image analysis with Aperio ImageScope. For quantification of positive areas, the Positive Pixel Count V9.1 algorithm was used (pixel area/mm^2→2.44827×10^-2). Three biological replicates per condition were used to quantify the Sirius red-positive area. Data are displayed as number of pixels in positive area versus number of pixels in total area (=positivity).

BMP-9 ELISA
An ELISA for mouse BMP-9 was developed. Nunc maxisorp plates (Nunc, Denmark) were coated with mouse anti-human BMP-9 antibodies (1 μg/mL in PBS, R&D Systems, Abington, UK) O/N at room temperature (RT). Between all steps, plates were washed with PBS containing 0.05% Tween-20 (Merck). Plates were blocked with 5% Tween-20, 0.05% sodium azide in PBS for 1 hour, followed by incubation with plasma samples (50 μL diluted with 1% bovine serum albumin (BSA) (PAA, Germany)/PBS) or a standard (recombinant mouse BMP-9, R&D Systems) for 2 hours at RT. Detection was performed with biotinylated goat anti-human BMP-9 antibodies (0.2 μg/mL in 1% BSA/PBS 2 hours, RT), streptavidin-horse radish peroxidase and a substrate reagent pack (all R&D Systems) as described previously.36 37
CCl4 animal experiments
Male Balb/c mice (five animals per group) weighing 20–25 g and 8 weeks old were used for the CCl4 time-course experiments. Liver injury was induced by intraperitoneal injection of 1.6 g/kg body weight of CCl4 (CCl4 was mixed 1:8 with mineral oil). Male C57BL/6 mice were used for chronic liver injury studies. Male C57BL/6 mice were used for acute liver injury studies. Mice received one intraperitoneal injection of either lipopolysaccharide (LPS) (1 μg/g body weight), CCl4 (1.6 g/kg body weight) or PBS (control). In addition, one group of animals received recombinant BMP-9 (100 ng per mouse) alone every 24 hours or in combination with the LPS/CCl4 injections. Mice were sacrificed at the times indicated in the figures, and blood and livers were collected.

Partial hepatectomy
Two-third partial hepatectomy (PH) experiments with mice were carried out as described. Half of the mice additionally received recombinant BMP-9 every 24 hours as described above. Mice were sacrificed at the times indicated in the figures, and blood and livers were collected.

Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections were dewaxed and rehydrated through a graded ethanol series and incubated at 60°C for 60 min. Antigen unmasking was performed using a citrate buffer (0.01 M sodium citrate pH 6) in a water bath at 95°C for 20 min followed by cooling in distilled water. Tissues were covered with some drops of ‘Dual Endogenous Enzyme Block’ in a humid atmosphere for 15 min. After sections were washed with PBS, they were incubated with the diluted first

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Forward sequence</th>
<th>Reverse sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acta2 (αSMA)</td>
<td>GCTGAGAATGCCGATGAGCAG</td>
<td>GGTCTCAAAACAGTTCTGGTCA</td>
</tr>
<tr>
<td>ActRIIB</td>
<td>AGGCAGACCTTCGAGAAGCAG</td>
<td>CCTTGCCCAGCTATGTCAG</td>
</tr>
<tr>
<td>Albumin</td>
<td>CAGAACTGGAAGAAAAGAGATC</td>
<td>GCCCATGAGTTTGGCTC</td>
</tr>
<tr>
<td>ALK1</td>
<td>GCCCTTTTCGTGCTG</td>
<td>ATGCCCGCCGAGAACATG</td>
</tr>
<tr>
<td>ALK2</td>
<td>GTGGAGATTTACAAAGCCACCA</td>
<td>GGCTGGAAGAACCCTGTGAGG</td>
</tr>
<tr>
<td>BMP-9</td>
<td>CAGAATCTGGAAGAACAGATC</td>
<td>GCCCTTGAGTTTGGCTC</td>
</tr>
<tr>
<td>β-Actin</td>
<td>GGCTGCCGATCTGCTCAGT</td>
<td>CAGATGGTTCAACAGCAGT</td>
</tr>
<tr>
<td>j2 Microglobulin</td>
<td>TCTGTGTTGGTGCTACTGA</td>
<td>CAGTAGTGGTCCTCCACTTC</td>
</tr>
<tr>
<td>CD11b</td>
<td>AACACACTCAGTCCAGAGA</td>
<td>CGTGGTACCCGACTGTTA</td>
</tr>
<tr>
<td>Col1a1</td>
<td>TCAAGAGGGAAGAAGCAGAT</td>
<td>CCAAGATCTGGAGTGTA</td>
</tr>
<tr>
<td>Desmin</td>
<td>TACACCTGCGAGATTGATGC</td>
<td>ACATCCAAGCCCATCTTCAC</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>ACTGTGAAGGGACGGTCAAC</td>
<td>GGAGACAGAGAGATGAATC</td>
</tr>
<tr>
<td>Endoglin</td>
<td>CACCTGCGACTCCCTCTC</td>
<td>GCAAACGTCACTCCACC</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>ATGGGGGGAACCGTAC</td>
<td>GCGAGGAGAAGAAGAAGAAG</td>
</tr>
<tr>
<td>Gusb</td>
<td>AAAATGGAGTGCGTGTTGGGTCG</td>
<td>CCACTTTCCGTTCAAGGCA</td>
</tr>
<tr>
<td>Hnf4α</td>
<td>ATACCAATGCAGAAGAAGG</td>
<td>AACAGATACCACACTGGGAA</td>
</tr>
<tr>
<td>Id1</td>
<td>GGATGGATATGGCCGACTAC</td>
<td>TTCAGATGGGGACGTGTCATT</td>
</tr>
<tr>
<td>Lyve-1</td>
<td>CGACACACACTCGCTGTTA</td>
<td>CGCAGCATGTCCTGAGTA</td>
</tr>
<tr>
<td>Mki67</td>
<td>ATACATCGGCGCTTGTAG</td>
<td>GCTGCCGATGTTGCTC</td>
</tr>
<tr>
<td>Pcna</td>
<td>TACACCTGACTCTGCGTCC</td>
<td>TGTTGCTACTTACCTGAGG</td>
</tr>
<tr>
<td>Pdgfb</td>
<td>CATCGTACCTGCTTTCCTCTCTC</td>
<td>GTGCTCGGCTACCTGAGG</td>
</tr>
<tr>
<td>Peptidylprolyl isomerase A</td>
<td>CAAATGCTGGACCAACACACAGC</td>
<td>GTTACGCTTCTTTTACCTCC</td>
</tr>
<tr>
<td>Ppar</td>
<td>AGCTGCGATGACGTGATCTGTGA</td>
<td>CGGTGGTTTCTTGGTCGGT</td>
</tr>
<tr>
<td>Smad6</td>
<td>AGATTTCCTGACGCTTACTC</td>
<td>CCGTACCAGGATCTGAGG</td>
</tr>
<tr>
<td>Sna1</td>
<td>CAATATAGGAGCAGCTGGAAGA</td>
<td>ACTGCAGGAGACGGTACAT</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>GGTACCCGCTGCTG</td>
<td>CAGAAATGGCGCTGAG</td>
</tr>
<tr>
<td>CTGF</td>
<td>GGGCTCTCCCTGAGGATTC</td>
<td>ATCCGCGAAATGCGAGGTA</td>
</tr>
<tr>
<td>VEGF-A</td>
<td>ACCAGATGAAGGACGCTGGAAGA</td>
<td>AAGAGGACGAGTCAAGG</td>
</tr>
<tr>
<td>Vimentin</td>
<td>CGGCTGAGAGAAGAAGAAGAAG</td>
<td>CCACTTTCCGTTCAAGGCA</td>
</tr>
</tbody>
</table>

ALK, activin receptor-like kinase; αSMA, smooth muscle actin; BMP, bone morphogenetic protein; CTGF, connective tissue growth factor; Pcna, proliferation cell nuclear antigen; Smad, small mothers against decapentaplegic; TGF, transforming growth factor; VEGF, vascular endothelial growth factor.

Contents


Table 1 Sequences of the mouse primers used for real-time PCR (always in 5’≥3’ orientation)

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Forward sequence</th>
<th>Reverse sequence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acta2 (αSMA)</td>
<td>GCTGAGAATGCCGATGAGCAG</td>
<td>GGTCTCAAAACAGTTCTGGTCA</td>
</tr>
<tr>
<td>ActRIIB</td>
<td>AGGCAGACCTTCGAGAAGCAG</td>
<td>CCTTGCCCAGCTATGTCAG</td>
</tr>
<tr>
<td>Albumin</td>
<td>CAGAACTGGAAGAAAAGAGATC</td>
<td>GCCCATGAGTTTGGCTC</td>
</tr>
<tr>
<td>ALK1</td>
<td>GCCCTTTTCGTGCTG</td>
<td>ATGCCCGCCGAGAACATG</td>
</tr>
<tr>
<td>ALK2</td>
<td>GTGGAGATTTACAAAGCCACCA</td>
<td>GGCTGGAAGAACCCTGTGAGG</td>
</tr>
<tr>
<td>BMP-9</td>
<td>CAGAATCTGGAAGAACAGATC</td>
<td>GCCCTTGAGTTTGGCTC</td>
</tr>
<tr>
<td>β-Actin</td>
<td>GGCTGCCGATCTGCTCAGT</td>
<td>CAGATGGTTCAACAGCAGT</td>
</tr>
<tr>
<td>j2 Microglobulin</td>
<td>TCTGTGTTGGTGCTACTGA</td>
<td>CAGTAGTGGTCCTCCACTTC</td>
</tr>
<tr>
<td>CD11b</td>
<td>AACACACTCAGTCCAGAGA</td>
<td>CGTGGTACCCGACTGTTA</td>
</tr>
<tr>
<td>Col1a1</td>
<td>TCAAGAGGGAAGAAGCAGAT</td>
<td>CCAAGATCTGGAGTGTA</td>
</tr>
<tr>
<td>Desmin</td>
<td>TACACCTGCGAGATTGATGC</td>
<td>ACATCCAAGCCCATCTTCAC</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>ACTGTGAAGGGACGGTCAAC</td>
<td>GGAGACAGAGAGATGAATC</td>
</tr>
<tr>
<td>Endoglin</td>
<td>CACCTGCGACTCCCTCTC</td>
<td>GCAAACGTCACTCCACC</td>
</tr>
<tr>
<td>Fibronectin</td>
<td>ATGGGGGGAACCGTAC</td>
<td>GCGAGGAGAAGAAGAAGAAG</td>
</tr>
<tr>
<td>Gusb</td>
<td>AAAATGGAGTGCGTGTTGGGTCG</td>
<td>CCACTTTCCGTTCAAGGCA</td>
</tr>
<tr>
<td>Hnf4α</td>
<td>ATACCAATGCAGAAGAAGG</td>
<td>AACAGATACCACACTGGGAA</td>
</tr>
<tr>
<td>Id1</td>
<td>GGATGGATATGGCCGACTAC</td>
<td>TTCAGATGGGGACGTGTCATT</td>
</tr>
<tr>
<td>Lyve-1</td>
<td>CGACACACACTCGCTGTTA</td>
<td>CGCAGCATGTCCTGAGTA</td>
</tr>
<tr>
<td>Mki67</td>
<td>ATACATCGGCGCTTGTAG</td>
<td>GCTGCCGATGTTGCTC</td>
</tr>
<tr>
<td>Pcna</td>
<td>TACACCTGACTCTGCGTCC</td>
<td>TGTTGCTACTTACCTGAGG</td>
</tr>
<tr>
<td>Pdgfb</td>
<td>CATCGTACCTGCTTTCCTCTC</td>
<td>GTGCTCGGCTACCTGAGG</td>
</tr>
<tr>
<td>Peptidylprolyl isomerase A</td>
<td>CAAATGCTGGACCAACACACAGC</td>
<td>GTTACGCTTCTTTTACCTCC</td>
</tr>
<tr>
<td>Ppar</td>
<td>AGCTGCGATGACGTGATCTGTGA</td>
<td>CGGTGGTTTCTTGGTCGGT</td>
</tr>
<tr>
<td>Smad6</td>
<td>AGATTTCCTGACGCTTACTC</td>
<td>CCGTACCAGGATCTGAGG</td>
</tr>
<tr>
<td>Sna1</td>
<td>CAATATAGGAGCAGCTGGAAGA</td>
<td>ACTGCAGGAGACGGTACAT</td>
</tr>
<tr>
<td>TGF-β1</td>
<td>GGTACCCGCTGCTG</td>
<td>CAGAAATGGCGCTGAG</td>
</tr>
<tr>
<td>CTGF</td>
<td>GGGCTCTCCCTGAGGATTC</td>
<td>ATCCGCGAAATGCGAGGTA</td>
</tr>
<tr>
<td>VEGF-A</td>
<td>ACCAGATGAAGGACGCTGGAAGA</td>
<td>AAGAGGACGAGTCAAGG</td>
</tr>
<tr>
<td>Vimentin</td>
<td>CGGCTGAGAGAAGAAGAAGAAG</td>
<td>CCACTTTCCGTTCAAGGCA</td>
</tr>
</tbody>
</table>
antibody at 4°C overnight. The corresponding secondary antibodies were added for 1 hour at RT. Sections were covered with 200 µL 3,3′-diaminobenzidine (DAB) substrate. Colour development was monitored under the microscope and the reaction was stopped by immersing the sections in distilled water for 5 min. Sections were counterstained in Mayer’s haemalum solution for several seconds and rinsed with water, followed by dehydration through ascending ethanol. Clearing was performed in xylene, and sections were mounted with malin oil.

Patient samples
Frozen human liver fibrosis samples were provided by the tissue bank of the National Center for Tumor Diseases (NCT, Heidelberg, Germany) in accordance with the regulations of the tissue bank and the approval of the ethics committee of Heidelberg University (Ethikvotes # 206/207, year: 2005).

Immunohistochemical stainings on human cryosections
Immunohistochemical stains were performed on an automated immunostainer with an iVIEW DAB detection kit (Ventana/ Roche, Tucson, USA) using primary BMP-9 antibody (1:500, Bio rad) and counterstained with haematoxylin. All slides were evaluated by at least one board certified surgical pathologist.

Statistics
Two-sided, unpaired Student’s t-test was used to identify significant differences between groups. Classification of significances was determined as follows: p<0.05 = *; p<0.01 = **; p<0.001 = ***.

RESULTS

HSCs are source and target of BMP-9 in mouse liver
To molecularly dissect hepatic functions of BMP-9, we first analysed which cell type of the healthy liver expresses the highest levels of BMP-9 mRNA. Towards this end, we isolated four different liver cell types (HC, HSC, LSEC and KC) simultaneously from livers of healthy male mice and directly lysed the cells for RNA purification. Successful enrichment of individual cell types was verified by analyses of expression levels of specific cell-type markers (see online supplementary figure S1). HSCs express highest levels of BMP-9 mRNA (figure 1A). Analysis of BMP-9 receptor expression revealed a heterogeneous expression pattern with each cell type expressing at least one of the two high-affinity receptors: ALK1 or ActRIB. HSCs and LSECs also expressed similar levels of ALK2, an alternative type I receptor for BMP-9 with lower affinity, as well as endoglin, a co-receptor for BMP-9 signalling (see online supplementary figure S2).

Cultured HSCs are known to spontaneously activate and differentiate into myofibroblasts. Therefore, we analysed BMP-9 expression dynamics (RNA and secreted protein) during in vitro activation. Both, mRNA expression and protein secretion of BMP-9 significantly increased in culture and maintained at elevated levels at least for 1 week (figure 1B, C). Furthermore, BMP-9 directly enhanced the wound-closure potential (determined by scratch assay) of the human HSC cell line, LX-2 (figure 1D) and stimulated migration of cultured primary human HSCs (figure 1E). While BMP-9 did enhance proliferation of cultured HSCs (LX-2 as well as primary human HSCs; figure 1F, G), it had no modulatory effect on the expression of markers associated with the in vitro activation process (figure 1H, I). Stimulation with TGF-β was used as positive control in these experiments and led to statistically significant changes as expected (upregulation of Col1α1, fibronectin and Pdgfb and downregulation of Ppary). Consistently, culturing primary mouse HSCs in the presence of BMP-9 neutralising ALK1-Fc did not change expression of activation markers, indicating that the cells activate in vitro even without BMP-9 (figure 1H).

BMP-9 stabilises epithelial properties of primary HCs
BMP-9 has been described as a vascular quiescence factor, stabilising the differentiated phenotype of mature endothelial cells. Primary HCs and hepatoma cell lines are responsive to BMP-9. Primary mouse HCs stimulated in culture with recombinant BMP-9 displayed upregulation of typical BMP-target genes including Id1, hepcidin (hamp1) or Snail6 (figure 2A). BMP-9 inhibited baseline as well as HGF-induced HC proliferation (figure 2B). Primary HCs cultured as monolayer rapidly lose their epithelial phenotype and acquire mesenchymal properties (epithelial to mesenchymal transition (EMT))40 41. As shown in figure 2C, BMP-9 dose dependently reversed the culture-provoked upregulation of mesenchymal markers like collagen I and fibronectin, as well as downregulation of the epithelial marker E-cadherin. In addition, TGF-β-mediated induction of the EMT transcription factor Snail12 was inhibited by BMP-9 (see online supplementary figure S3). Similarly, BMP-9 enhanced RNA expression of 23 out of 37 tested enzymes and other proteins involved in metabolic activities of HCs (figure 2D). To further investigate the role of BMP-9 in stabilising the HCs’ epithelial phenotype, we isolated primary HCs from the livers of BMP-9 KO mice and measured the expression levels of three mesenchymal and three epithelial marker genes. The result shown in figure 2E demonstrates that without BMP-9 HCs express significantly higher levels of mesenchymal and lower levels of epithelial markers, compared with cells isolated from wild-type livers.

BMP-9 expression is transiently reduced under conditions of acute liver damage
To assess whether BMP-9 levels might change under conditions of liver damage in vivo, hepatic BMP-9 mRNA expression levels were determined in three different animal models of acute liver damage: single injections of CCl4 or LPS and liver regeneration upon removal of 2/3 of the liver (PH). There was a transient downregulation of BMP-9 expression shortly after onset of damage in all three models (figure 3A–C). At later time points, BMP-9 expression was elevated on LPS or CCl4 injection (figure 3A–C). Furthermore, LPS treatment downregulated BMP-9 expression in cultured HSCs (figure 3D).

Corresponding to the observed antiproliferative effects of BMP-9 on HCs (figure 2B), the drop of BMP-9 expression after PH (figure 3C) as well as after one injection of CCl4 (figure 3A) coincided with previously described time points of enhanced HC proliferation, which peaks 24–48 hours after PH18 and 48–72 hours after CCl4 injection. In line with this, expression levels of the proliferation cell nuclear antigen were rapidly upregulated after a single injection of LPS and thereby opposed the BMP-9 levels at early time points (8 hours; figure 3B). We next examined the outcome of counterbalancing the downregulation of endogenous BMP-9 expression by exogenous BMP-9 at early time points after induction of damage. Indeed, injection of recombinant BMP-9 resulted in a significant enhancement of liver damage as reflected by increased circulating levels of lactate dehydrogenase (LDH), aspartate aminotransferase (AST) and alanine transaminase (ALT) on day 2 after PH (figure 4A). Moreover, overall proliferation was significantly reduced in BMP-9-treated animals (figure 4B), in spite of enhanced mRNA expression of the proliferative cytokines CTGF and VEGF (figure 4C).
Hepatic stellate cells (HSCs) are source and target of bone morphogenetic protein (BMP)-9. (A) Four different liver cell types (hepatocytes (HCs), HSCs, liver sinusoidal endothelial cells (LSECs) and Kupffer cells (KCs)) were simultaneously isolated from healthy mouse livers, directly lysed and total RNA was purified. BMP-9 expression levels were determined by real-time PCR. Data are expressed as average values±SD (derived from n=8 isolations). Because no housekeeping gene was equally expressed in all cell types, the ΔCt for BMP-9 versus the average Ct of all four samples per experiment was calculated and expressed as % of total expression. (B) BMP-9 mRNA levels during in vitro activation (up to 6 days of culture) of primary mouse HSCs. Significant changes are indicated in relation to the 1-day time point. Ct values for BMP-9 were normalised to the housekeeping gene Ppia. (C) BMP-9 secretion from in vitro activated HSCs, measured by ELISA using samples from the conditioned medium of cultured primary mouse HSCs. Significant changes are indicated in relation to the 1-day time point. (D) Scratch assay, performed with LX-2 cells (human HSC cell line). (E) Migration assay, performed with primary human HSCs (average±SD of n=7 cell isolations). LX-2 (F) or primary human HSCs (passage 3–5) (G) were cultured with or without BMP-9 (5 ng/mL) for 72 hours and cells were counted. As positive internal control, LX-2 cells were stimulated with platelet derived growth factor (PDGF)-BB (20 ng/mL) as indicated. The graphs show the average cell numbers (for LX-2 (F): n=3 experiments; for (G) primary cells from four different donors were used)±SD. (H) Expression of HSC activation markers (Col1a1, fibronectin (fn), PDGF-B (pdgfb), Pparγ (pparg) and αSMA) was determined by real-time PCR in primary mouse HSCs (average of n=3 cell isolations±SD) 24 hours after stimulation as indicated. (I) Primary human HSCs (passage 3–5, derived from three different donors) were stimulated with BMP-9 (5 ng/mL) for 72 hours and expression of Col1a1 was determined by real-time PCR. Statistical differences were classified as follows: *p<0.05; **p<0.001; ***p<0.0001. ALK, activin-like kinase; Ppia, peptidylprolyl isomerase A; αSMA, α smooth muscle actin; TGF, transforming growth factor; ut, untreated.
Figure 2  Effects of bone morphogenetic protein (BMP)-9 on primary mouse hepatocytes in vitro. (A) Induction of mRNA expression of classical BMP-target genes (Id1, hepcidin and Smad6) was analysed by real-time PCR. Data are expressed as average values±SD. Ct values for the target genes were normalised to the housekeeping gene β-actin. Significant changes are indicated in relation to the corresponding time point of the untreated (ut) samples. (B) Using a Sybr Green I-based assay DNA levels in hepatocytes were determined within 48 hours of culture with the indicated stimulations. Addition of hepatocyte growth factor (HGF) (40 ng/mL) potently triggered DNA synthesis which was attenuated by co-treatment with BMP-9 (5 and 50 ng/mL). (C) Real-time PCR results showing that with prolonged culture of primary hepatocytes, the cells continuously induce expression of mesenchymal proteins like collagen 1a1 and fibronectin and reduce expression of the epithelial cadherin (E-Cadherin). In the presence of BMP-9, these regulations were significantly inhibited. Data are expressed as in panel A. (D) Hepatocytes were cultured in the presence or absence of BMP-9 (5 ng/mL) for either 24 hours (0 ≥ 24 hours), 48 hours (0 ≥ 48 hours) or first for 24 hours without and then another 24 hours with BMP-9 (24 hours ≥ 48 hours) and the mRNA expression levels of 37 proteins involved in drug metabolism processes were investigated by real-time PCR using Fluidigm analyses. The heatmap illustrates changes of ADME gene expression signatures in hepatocytes upon BMP-9 treatment and shows that approximately 60% of analysed genes are higher expressed (threshold 1.5-fold, marked with big asterisk) at least at one time span upon BMP-9 stimulation. (E) Expression of mesenchymal and epithelial marker genes were analysed by real-time PCR in freshly isolated hepatocytes from wild-type versus BMP-9 KO mice. Statistical differences were classified as follows: *p<0.05; **p<0.001; ***p<0.0001.
Lack of BMP-9 in vivo ameliorates liver fibrosis upon repeated injections of CCl4

To analyse long-term BMP-9 effects, we interfered with BMP-9 signalling, using an adenovirus expressing a soluble form of the BMP-9 type I receptor, ALK1 (AdALK1-Fc). In contrast to BMPs, TGF-β first binds to its type II receptor (TβRII). TGF-β/TβRII complex associates only thereafter with a type I receptor. The direct affinity of TGF-β alone to any type I receptor (ALK1 or ALK5) is low (reviewed in 44). Therefore, ALK1-Fc protein selectively targets BMP-9 and does not inhibit TGF-β signalling. To verify this and to also confirm that ALK1-Fc did not neutralise the effects of other BMPs, we performed western blot analyses for phosphorylated SMAD proteins (see online supplementary figure S4A, B). SMAD-1 phosphorylation by BMP-9 was efficiently inhibited by ALK1-Fc (see online supplementary figure S4C). Moreover, chronic CCl4-treated mice that received AdALK1-Fc had strongly reduced levels of circulating BMP-9 compared with those receiving CCl4 and a control virus AdFc (see online supplementary figure S4C).

Using this approach, we next examined the consequences of BMP-9 neutralisation under conditions of chronic liver damage. Liver fibrosis in mice was experimentally induced by repeated injections of CCl4. One group of animals served as solvent control (CCl4+saline), a second group received a control virus (CCl4+AdFc) and BMP-9 was neutralised in the third group by injecting an adenovirus expressing ALK1-Fc (CCl4+AdALK1-Fc). Animals receiving repeated injections of CCl4 for 4 weeks developed fibrosis, which was significantly reduced by AdALK1-Fc (figure 5A, B). When analysing RNA levels for collagen in the livers of these animals, we found a correspondingly reduced expression in the AdALK1-Fc group (figure 5C). Expression of the BMP target gene Id1 was also strongly reduced, implying that BMP-9 induced Id1 expression during fibrogenesis, which was in line with our previous observation that HSCs upregulate Id1 expression during activation.27 The data further show that BMP-9 expression (just like that of TGF-β) increases with fibrosis development. While this rise in BMP-9 levels was strongly prevented by AdALK1-Fc, TGF-β levels remained elevated (figure 5C). Immunostaining for cleaved caspase-3 showed significantly reduced overall apoptosis rates in AdALK1-Fc-treated animals (figure 5D). Robustness of these results was confirmed in mice with genetic depletion of BMP-9 in the CCl4-induced liver fibrosis model, where lack of BMP-9 signalling in BMP-9 knockout mice led to a milder development of fibrosis, as compared with controls (figure 6A). As in the AdALK1-Fc setup, upregulation of Id1 protein was significantly reduced in the CCl4-treated BMP-9 KO mice compared with the wild types (figure 6B, C). Also here, BMP-9 mRNA expression was induced by CCl4 in the wild types and TGF-β mRNA expression was still enhanced even in the absence of BMP-9 and despite a decreased fibrosis (figure 6D). In accordance with the Sirius red staining results shown in figure 6A, induction of Col1a1 was significantly reduced in the KO mice (figure 6D). Changes in fibronectin and desmin expression were not significantly different between CCl4-treated wild types and BMP-9 KO mice but in both cases basal expression was enhanced in the BMP-9 KO mice (see online supplementary figure S3B). In contrast to the AdALK1-Fc approach, upregulation of the BMP-target gene Id1 still also occurred in the absence of BMP-9 (figure 6D), which might be the result of adaptations in the BMP signalling network which had time to develop in the KO mice but not in the AdALK1-Fc-treated animals. Hepcidin, another BMP-target gene, was not changed by CCl4, but was generally reduced by AdALK1-Fc.
almost absent in the BMP-9 KO mice (see online supplementary figure S5B), indicating that without BMP-9 hepcidin seems to be generally low expressed. Smad6 expression was unchanged in KO mice compared with wild types and although there was a tendency of reduced expression of the epithelial marker E-Cadherin in the KO mice, in whole liver lysates this difference was not statistically relevant (see online supplementary figure S5B). As expected, the liver damage markers AST and ALT showed a clear tendency of reduction in the serum of the CCl₄-treated KO mice compared with wild type (see online supplementary figure S5B) further evidencing a decreased liver damage in the BMP-9 KO mice. Overall proliferation in the CCl₄-treated KO mice as determined by immunostaining against Ki67 was significantly reduced compared with the wild-type animals (figure 6E).

Thus, two different experimental approaches both supported the conclusion that high levels of BMP-9 facilitate CCl₄ induced liver fibrogenesis in mice.
Potential role of BMP-9 in human liver fibrosis

To address the question if our results with mice are transferable to the human situation, we performed immunostaining against BMP-9 in cryosections from normal and fibrotic human livers (figure 7). We found positive staining in normal liver in stellate-shaped, non-parenchymal cells and in the walls of larger blood vessels as well as in normal liver in stellate-shaped, non-parenchymal cells and in the walls of larger blood vessels.
vessels, especially with onset of HSC activation (early fibrogenesis). This pattern fits well with the hypothesis that also in human liver HSCs located at the sinusoids and in the walls of larger vessels are principally positive for BMP-9 synthesis. Bile duct epithelium appeared rather negative. In line with this, in moderate fibrosis positive staining was found in those areas where activation of HSCs can be expected. In fully established fibrotic septae, staining seemed to be less intense, though still present.

When searching publicly available array data with human liver samples, we found two cohorts which investigated normal liver samples versus hepatitis-B-virus (HBV)-mediated damage (see online supplementary figure S6A, B). BMP-9 itself was significantly upregulated in the samples from patients with acute liver failure (GSE38941), but not significantly changed with increasing fibrosis stages (GSE84044). The co-receptor endoglin was significantly enhanced in samples of fibrosis stages 2 and 4 (GSE84044), but not in the acute liver failure cohort (GSE38941). However, expression of the BMP-9 receptor ALK1 was significantly upregulated in both cohorts, indicating that under conditions of damage the number of ALK1-positive cells and thereby the sensitivity and responsiveness to BMP-9 stimulation increases. Thereby local elevations of BMP-9 might directly affect the cellular crosstalk, for example, between activated HSCs and LSECs.

**DISCUSSION**

Although BMP-9 is constitutively expressed in healthy liver, knowledge about its physiological functions is still very limited (for review, see). Whereas inhibition of BMP-9/ALK1 signaling is already discussed as a potential anti-angiogenic strategy in cancer and clinical application of rhBMP-9 was recently presented as a potentially promising new approach to promote fracture healing, its possible roles during acute or chronic liver
damage were only insufficiently investigated up to now. In the present work, we therefore addressed this point and investigated BMP-9 expression levels, cellular responses and in vivo consequences of BMP-9 signalling in liver cells in vitro as well as in diverse mouse models for acute and chronic liver damage.

The results demonstrate that (1) the HSC is the main BMP-9-producing cell type in the liver, (2) BMP-9 expression further increases when HSCs become activated leading to higher levels during fibrogenesis, (3) neutralisation of BMP-9 ameliorates fibrogenesis and (4) BMP-9 stabilises the epithelial properties of HC and controls their proliferation in vitro as well as in vivo at early time points after acute damage.

**Profibrogenic action of BMP-9**

The finding that the liver is the main organ that produces BMP-9 (at least under healthy conditions) seems undoubted,

but the exact hepatic cell type secreting BMP-9 was controversially reported. Miller et al

detected high BMP-9 expression in rat liver, and specified non-parenchymal cells (HSC, LSEC and KC) but not HCs as producing cell types. Another study using human samples confirmed the highest expression of BMP-9 in liver but when analysing commercially obtained RNA samples from diverse human liver cell types ( bile duct cells, HCs, HSCs and LSECs), they found highest BMP-9 expression in bile duct cells followed by HCs and only rather low expression in HSCs and LSECs.17 Our results confirm the data of Miller et al showing highest BMP-9 transcript expression in HSCs (figure 1A). HCs, in contrast, expressed very low, almost undetectable levels. Although we did not find evidence for a direct enhancement of activation in vitro (no significant induction of αSMA, collagen I, fibronectin or Pdgfb mRNA expression by BMP-9 stimulation and no reduction of Pparγ; figure 1H, I), these cells obviously produce BMP-9 under quiescent conditions, which is further enhanced on fibroblastic activation in vitro (figure 1B, C). This finding implied that liver fibrogenesis might be accompanied by enhanced presence of BMP-9 in vivo. Consistently, BMP-9 and its direct target gene Id1 are strongly upregulated at the transcript level in fibrotic livers of mice that received repeated

**Figure 6** Continued
injections of CCl₄ (figures 5C and 6D). We further document enhanced HSC migration and proliferation by BMP-9. Based on this and the increased BMP-9 secretion from activated HSCs, locally high levels of BMP-9 at sites of liver damage where fibrosis develops can be expected and were indeed observed by immunostaining of fibrotic human liver samples (figure 7). To analyse if elevated BMP-9 expression is indeed functionally related to fibrogenesis under conditions of chronic damage (repeated injections of CCl₄), we used two different approaches: first, we adenovirally overexpressed a soluble form of the BMP-9 receptor ALK1 (by AdALK1-Fc), which binds and thereby neutralises BMP-9 protein. Because neither TGF-β nor other BMPs (except BMP-10) exert high affinity to ALK1 alone (in the absence of a type II receptor), ALK1-Fc selectively neutralises BMP-9 (see online supplementary figure S4). In the second approach, we used BMP-9 KO mice. On repeated injections of CCl₄ for several weeks, all mice developed liver fibrosis. When BMP-9 was neutralised (by ALK1-Fc) or absent (in the KO mice), the degree of fibrosis was clearly reduced (figures 5 and 6). These data suggest that in the context of chronic liver injury, BMP-9 aggravates liver fibrogenesis in vivo. The underlying mechanism most likely involves enhanced migration and proliferation of activated HSCs (figure 1D–G) and at least in the AdALK1-Fc model also induction of Id1 which we had already earlier identified as a fibrosis-regulating factor. In the KO mice treated with CCl₄, Id1 expression was still significantly upregulated (figure 6D) which could be a result of adaptation processes that may have occurred in these mice. Since LSECs can directly control HSC activation and the BMP-9 receptor ALK1 was highly expressed in freshly isolated LSECs (see online supplementary figure S2), the profibrogenic effects of BMP-9 that we observed might as well be the result of a cellular cross-talk between HSCs and LSECs. In line with this hypothesis, we found significantly enhanced ALK1 expression in fibrotic human samples as derived from publically available array data with human liver samples (GSE38941 and GSE84044; online supplementary figure S6A, B) implying that the sensitivity of liver cells to BMP-9 stimulation should increase with fibrogenesis.

**BMP-9 functions as stabiliser of HC epithelial properties**

It is well established that isolated HCs in culture rapidly lose their epithelial and functional properties and that they spontaneously undergo a dedifferentiation process towards a mesenchymal cell type. This process, which exerts features of an EMT, is further enhanced in the presence of TGF-β. On EMT,
HCs downregulate expression of many enzymes and genes needed for proper metabolic functions of the liver. The conclusion from these findings is that only polarised (epithelial) HCs are capable of efficiently processing xenobiotics or endogenous substances. On the other hand, under conditions of damage or on malignant transformation of HCs, EMT enables the cells to proliferate and to become motile. BMP-9 exerted significant antiproliferative and anti-EMT activities on primary cultured mouse HCs in vitro (see figure 2B, C and online supplementary figure S3). In addition, BMP-9 led to enhanced and preserved expression of important drug metabolising enzymes, especially cytochrome P450 oxidases (figure 2D) and BMP-9 KO HCs expressed significantly less epithelial and more mesenchymal markers than wild-type cells (figure 2E). These findings imply that the basal presence of BMP-9 in healthy liver might contribute to maintain functionality of parenchymal cells. Nevertheless, since BMP-9 knockout mice are viable and fertile, showing no overt phenotype, these basic hepatic functions of BMP-9 seem to be largely dispensable or can become compensated by other, so far not identified factors or mechanisms.

Our observation that BMP-9 acts as an antiproliferative and stabilising factor on primary HCs fits well to its previously reported properties as ‘quiescence factor’ for the (healthy) epithelium. Nevertheless, we and others also reported EMT-promoting effects of BMP-9 on hepatocellular carcinoma cells. This, together with the finding that BMP-9 neutralising agents are already in clinical trials as anti-angiogenic strategy against cancer growth, makes us conclude that at least in HCs and endothelial cells, BMP-9 exerts completely opposite functions in malignant versus non-malignant conditions. How these opposing functions are mechanistically mediated and controlled is not known but might be related to diverse expression levels of the individual receptors and co-factors, or might be brought about by crosstalk of BMP-9 signalling with other pathways.

On acute liver damage, BMP-9 needs to be transiently downregulated

We then investigated the hepatic expression levels of BMP-9 in three different mouse models of acute liver damage/regeneration, namely PH and single injections of either LPS or CCl₄. In each of these models, we found a transient reduction of BMP-9 expression levels at early time points (figure 3A–C).

Considering that almost any kind of liver injury goes along with an increase of gut-derived bacterial toxins such as LPS in the blood, it is well conceivable that this effect of acute liver injury on BMP-9 expression may be due to inhibitory effects of LPS on HSCs, which represent the major source of BMP-9 (figure 1A). In line with this assumption, LPS treatment results in a downregulation of BMP-9 levels in liver tissue in vivo (figure 3B) and strongly suppresses BMP-9 expression levels in HSCs (figure 3D) in vitro. Similar to KCs and sinusoidal endothelial cells, HSCs also express the LPS receptor Toll like receptor (TLR)-4 and respond to LPS treatment with proinflammatory signalling. We further found that counteracting such drop of BMP-9 in vivo 2 days after PH resulted in significantly enhanced liver damage (figure 4A). In accordance with the above-described antiproliferative effects of BMP-9 on HCs, these animals showed a reduced level of Mkι67-positive cells (figure 4B). This was accompanied by significantly upregulated expressions of the proproliferative cytokines VEGF and CTGF mRNA (figure 4C), which might be a mechanism of compensation of the antiproliferative effect of BMP-9.

These data support the concept that rapid reduction of BMP-9 expression (possibly via LPS) after acute damage might be needed to allow for transient HC proliferation and plasticity, features that are essential for optimal wound healing. Ongoing studies aim at further analysing the interplay of BMP-9 with LPS and its possible role in modulating inflammatory processes in the liver.

Under conditions of chronic damage (repeated injections of CCl₄), absence or neutralisation of BMP-9 reduced fibrogenesis and in this context overall proliferation was also reduced (figure 5D) indicating that the antiproliferative effects of BMP-9 on HCs might be rather important during acute damage than during chronic processes. This hypothesis is supported by our observation that the rapid reduction in BMP-9 expression in the three models of acute damage (figure 3A–C) always correlated with the onset of HC proliferation (for the LPS injection model this is shown in figure 3B, for CCl₄ injection and partial hepatectomy the proliferation time courses have been reported previously), similar to the results previously published by Mogler et al and Hoehme et al.

At first sight, it may seem contradictory that BMP-9 on the one side optimises HC polarisation and function, but on the other side high levels of BMP-9 seem to generally enhance liver damage. We think that the functions of BMP-9 as a stabiliser of the parenchyma—although possibly beneficial under healthy conditions—might become impedimental under conditions of damage, where actions such as proliferation and plasticity are essentially needed, at least transiently. In addition, it seems very probable that BMP-9 might indirectly affect HSC activation and fibrogenesis by acting on other BMP-9-responsive liver cell types, like LSEC, which we showed to express even higher levels of all tested BMP-9 receptors than HSC (see online supplementary figure S2). For example, capillarisation of LSECs, a feature associated with liver damage including fibrogenesis, might be affected by high levels of BMP-9.

In summary, our data show that increasing levels of BMP-9 under conditions of damage pave the way to liver fibrogenesis, whereas absence or inhibition of BMP-9 supports the road to wound healing and liver regeneration. If this concept can be further confirmed in human, neutralisation of BMP-9 could become an important therapeutic approach to maximise the efficiency of antifibrotic medications of the liver, and possibly other organs. Up to a certain degree of damage, even the sole, transient inhibition of endogenous BMP-9 activity might suffice to allow for better liver regeneration and healing.

Author affiliations
1Department of Medicine II, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
2Division of Vascular Oncology and Metastasis, German Cancer Research Center Heidelberg (DKFZ-ZMBH Alliance), Heidelberg, Germany
3Department of Biochemistry and Molecular Biology II, Faculty of Pharmacy, Complutense University of Madrid, Sun Carlos Clinical Hospital Health Research Institute (IdiSCC), Madrid, Spain
4Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology and University of Tuebingen, Stuttgart, Germany
5German Red Cross Blood Service Baden-Württemberg-Hessen and Institute for Transfusion Medicine and Immunohaematology, Goethe University, Frankfurt, Germany
6Department of Gastroenterology and Hepatology, Beijing You’an Hospital, Affiliated with Capital Medical University, Beijing, China
7Department of Internal Medicine I, University Hospital Regensburg, Regensburg, Germany
8Applied Tumor Immunity Clinical Cooperation Unit, National Center for Tumor Diseases, German Cancer Research Center, Heidelberg, Germany
9Department of Gastroenterology, Hepatology and Infectious Diseases, University Hospital of the Heinrich-Heine University, Duesseldorf, Germany
10Division Systems Biology of Signal Transduction, DKFZ-ZMBH Alliance, German Cancer Research Center (DKFZ), Heidelberg, Germany
Acknowledgements

The authors are thankful to Alexandra Mueller, Katarina Abramovic and Emine Tuezien (Medical faculty Mannheim, Heidelberg University) for excellent technical assistance and Anne Dromp (University hospital at Mannheim) for providing TGF-β1 primer sequences.

Contributors

KB-H, AS, SD and PD did the planning for the study and are responsible for the overall content. Experiments were conducted by KB-H, CMe, CK, HG, AA, MT, EW, QL, FW, CH, MJH, SM-B, JA, MG, LJACH, CM, MPE, BH, HGA, AS, MT, EW, QL, FW, CH, MJH, SM-B, JA, MG, LJACH, SL, MW, CMo, CC, CE, BH, HGA, AS, MT, EW, QL, FW, CH, MJH, SM-B, JA, MG, LJACH, SL, MW, CMo, CC, CE.

Funding

This study was supported by Cancer Genomics Centre Netherlands and the Robert Bosch Foundation, Stuttgart, Germany, and the Forschungsförderung Wissenschaft, Forschung und Kunst Baden-Württemberg. None declared.

Competing interests

None declared.

Ethics approval

The tissue bank of the National Center for Tumor Diseases (NCT, Heidelberg, Germany) in accordance with the regulations of the tissue bank and the approval of the ethics committee of Heidelberg University (Ethikvotes # 206/207, year: 2005).

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES


